MedTrace Logo

A Dose-Response Safety Study of ENX-102 in Patients With GAD

NCT06653296 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-09-17

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of ENX-102 and determine a dose-response for the effects of ENX-102 in patients with GAD

Conditions

  • General Anxiety Disorder

Interventions

DRUG

ENX-102

Four weeks of ENX-102 (0.5, 1, or 3 mg) in capsule form followed by 2 weeks of tapered dose, taken orally once daily in the evening for a 6-week total treatment period

DRUG

Placebo

Six weeks of placebo in capsule form taken orally once daily in the evening for a 6-week total treatment period

Sponsors & Collaborators

  • Engrail Therapeutics INC

    lead INDUSTRY

Principal Investigators

  • Kimberly Vanover, PhD · Engrail Therapeutics INC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-09
Primary Completion
2025-06-23
Completion
2025-06-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06653296 on ClinicalTrials.gov